"Enalapril" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.
| Descriptor ID |
D004656
|
| MeSH Number(s) |
D12.644.456.345.360
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enalapril".
Below are MeSH descriptors whose meaning is more specific than "Enalapril".
This graph shows the total number of publications written about "Enalapril" by people in this website by year, and whether "Enalapril" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2020 | 1 | 3 | 4 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enalapril" by people in Profiles.
-
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021 09; 23(9):1518-1524.
-
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. JACC Heart Fail. 2020 10; 8(10):859-866.
-
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol. 2020 09 01; 76(9):1034-1048.
-
Improving physical activity and exercise capacity in heart failure. Taking the first step is always the hardest. Eur J Heart Fail. 2020 09; 22(9):1734-1736.
-
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020 02 01; 5(2):202-207.
-
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 02 07; 380(6):539-548.
-
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J. 2018 04; 198:145-151.
-
Placebo adherence and its association with morbidity and mortality in the studies of left ventricular dysfunction. J Gen Intern Med. 2010 Dec; 25(12):1275-81.
-
Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther. 2002 Oct; 24(10):1484-501.